EV Biologics, Inc. (YECO)
OTCMKTS: YECO · Delayed Price · USD
0.602
0.00 (0.00%)
Apr 19, 2024, 11:36 AM EDT - Market closed
Company Description
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics.
It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform.
The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces.
The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020.
EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
EV Biologics, Inc.
| Country | China |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 284 |
| CEO | Daniel S. McKinney |
Contact Details
Address: Eastern End Of Xiwuzhuang Village, Jiaodian Town, Xinhua Area Pingdingshan, Henan Province, F4 00000 China | |
| Phone | 86-375-8888988 |
| Website | evbiologics.com |
Stock Details
| Ticker Symbol | YECO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001607741 |
| CUSIP Number | 988497103 |
| ISIN Number | US9884971030 |
| SIC Code | 3270 |
Key Executives
| Name | Position |
|---|---|
| Daniel S. McKinney | Founder, Chairman and Chief Executive Officer |
| Monte Fisher | Chief Financial Officer |
| William Bossung | Corporate Finance Director and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2019 | 15-12B | Securities registration termination |
| Jun 26, 2019 | 8-K | Current Report |
| Apr 2, 2019 | 25-NSE | Filing |
| Apr 2, 2019 | 25-NSE | Filing |
| Apr 2, 2019 | 25-NSE | Filing |
| Apr 2, 2019 | 25-NSE | Filing |
| Mar 12, 2019 | 25-NSE | Filing |
| Mar 7, 2019 | 6-K | Report of foreign issuer |
| Feb 26, 2019 | 6-K | Report of foreign issuer |
| Feb 11, 2019 | 6-K | Report of foreign issuer |